Special Links








Hit Counter


Jerry Caulder

Hometown:  Gideon, Mo.

Current Residence: Rancho Santa Fe, Calif.

Major:  Zoology and Botany

Graduation Gideon High School:  1960




A day at work for Dr. Jerry Caulder could include a board meeting in New Zealand, guest lecturing at a university or researching a new investment opportunity.  Claiming “normal” days don’t exist in his life, the 1964 Southeast graduate has been presented a wealth of opportunities since he left Cape Girardeau.

Caulder continued his education at the University of Missouri and completed his doctorate in physiology and agronomy in 1969.  His career has subsequently included 15 years at Monsanto and tenures as chief executive officer for biotechnology firms Mycogen, Myelos, Xyris and Akkadix.  In August 2003, Caulder assumed the head role at Advanced Stent Technologies, a leading medical-device producer.

“The most rewarding thing about what I do is being involved in a technology (biotechnology) that creates products that really make a difference in our society—from new drugs and medical devices to improvements in our food chain,” he said.

Southeast allowed this sharecropper’s son from Gideon, Mo., to “step out into a whole new world.”  Caulder said his parents strongly believed education was the way to create choices in life.

“The education I received at Southeast created the ability for me to have choices,” he said.
He fondly recounts, “Everything was so new to a boy from the Bootheel—college sports, interacting with new people, the marathon poker games in Cheney Hall, the pool games, and all the time learning, learning and learning.”

Caulder suggests students become perpetual freshmen and never lose the enthusiasm or desire to learn.  The executive still follows this philosophy today as he lectures to high schools and universities, avidly reads, and has traveled to more than 100 countries.

Caulder’s ongoing list of accomplishments definitely demonstrates how to “Experience Southeast…Experience Success.”


Dr Jerry Caulder

Often called the "father of agbio" in the U.S., Jerry has an enviable record of success in the life science industry. His career began at Monsanto, where for 15 years he was responsible for the worldwide commercial development and introduction of all new agricultural products.

 He was the chairman and CEO of Mycogen, a highly successful agbio company started in the late 1980s and sold to Dow in 1998, and has held similar positions in a number of successful biotech business since then: Myelos, a therapeutic drug discovery company; Chlorogene, a therapeutic plant company; Athenix, an agbio company; Akkadix, a plant discovery and gene regulation company; and Advanced Stent Technologies, a medical device business.

 Jerry is involved with Burrill and Co, a San Francisco based biotech and agbio venture fund. He has been involved with non-biotech business as well, from pet food business (using waste products from corn processing) to golf club manufacturing. He has been involved in many local, state and national industry groups, is well recognized internationally and is a frequent speaker at industry forums.



Volume 1 // Number 1 // Article 10



Agricultural Biotechnology And Public Perceptions

Jerry Caulder

Xyris Corporation                                     

 Much of the debate concerning the acceptability of agricultural biotechnology can be traced to the fact that food is viewed as an entitlement in most of the developed world. In the United States (US), Europe, and other parts of the world, food is abundant. This abundant food supply is increasingly taken for granted, and treated cavalierly by consumers and government. On any given day, the US has less than forty-five days of food supplies, and these supplies are viewed as a "surplus". In contrast, two hundred years of oil supplies are viewed as a "strategic reserve".

All of us involved in agriculture must assume some responsibility for allowing such attitudes to persist. We have failed to raise public awareness about the economic significance of an adequate, safe, and affordable food supply. This failure to raise public awareness can be traced to two main problems. First, the economic benefit of improving nutrition, and food safety is very difficult to measure. How does one place a value on the improved nutritional content of food, or on food that is safer to eat? Second, there is the problem of how food safety issues are reported. A few people dying from food poisoning is newsworthy, while preventing millions from ever running such a risk is not.


In the case of agricultural biotechnology the record is even worse. Policy proposals based on "junk science" have gone unchallenged. A good example of how poor science has affected biotechnology products can be found in the area of food labeling. Food labeling should provide accurate information, based on scientific facts, not prejudice. In the past, the blood supply was labeled "Caucasian" or "Colored", not because of any differences in the quality of the blood, but simply because of social prejudice. This analogy carries through to food labeling. Labeling foods differently, simply because they are genetically engineered, is just another expression of another prejudice. Overwhelming scientific evidence suggests that genetically engineered food is no different from non-engineered food.


There are some 8,000 food products which are derived from soybeans that end up in the hands of consumers. Should we attempt to label each one individually because genetically modified soybeans may have been used as a raw material? And who should be responsible for such a task? Should we also label dairy products and milk derivatives, produced by cows fed with attrizine treated corn? How do we judge what is safe and what is not? What rules do we use to guide us if not those of science? It is socially undesirable to impose unreasonable costs on the consumer from labels with no informational content.


Labeling, of course, can be quite useful, and is desirable when valuable, accurate information is communicated to the consumer. Genetically engineered cotton has been engineered to produce natural blue fiber. If appropriately labeled, the non-use of chemical dyes can be communicated to consumers. Consumers allergic to dyes stand to benefit from the provision of this information. Genetically engineered tomatoes provide another example. Engineered tomatoes offer an extended shelf life. If appropriately labeled, such information is also of benefit to the consumer. In such cases, labeling is voluntary not mandatory. It is used to communicate factual information about services embodied in the product, and it is of economic value to the consumer.


Over the last few years we have surveyed the public about its attitudes towards agricultural biotechnology. I remain skeptical about the value of this exercise. Anyone involved in market research is aware that how a question is asked is as important as what the question is about. For example, if one frames the question as, We have learned how to use genetics in order to produce a tastier fruit with longer shelf life. Would you be interested?  the most likely answer will be "yes". But if one asks, We have learned how to manipulate plant genomes and we have transposed a gene to make the fruit tastier and longer lasting. Would you buy it?  the most likely answer will be "no thank you". This will especially be the case as the question is hypothetical and provides no additional information on which to make an informed choice.


Ultimately, the success of agricultural biotechnology will be decided in the market place. Past experience indicates that consumers can effectively sort through misinformation, and decide about the real value of new goods and services. When color TVs were introduced there were warnings about potential risks from "mutations". With microwave ovens there were warnings about risks of "abnormalities" from radiation. The widespread adoption of both technologies suggests that when scare tactics lack solid scientific evidence they tend to be short-lived. This will, no doubt, prove true for agricultural biotechnology as well.


The biotechnology industry must continue to create technology that enhances our ability to produce affordable, safe, high quality food. At the same time, the pressure on natural resources should be minimized. The government must also do its part. It must ensure the efficacy, quality, and safety of new products, while resisting the temptation to engage in social engineering. Questions of whether new products are desirable, or needed, are best answered by consumers in the market place, rather than by governments.


Agricultural biotechnology is still in its infancy. Its real impact on the world's capacity to produce safe food to feed an expanding population, or its impact on natural resources, will not be fully felt for many years. When history has been completed, and the economic and social impacts of biotechnology have been fully accounted for, scare tactics and social prejudice will not even occupy a footnote.


Suggested citation: Caulder, Jerry. (1998). Agricultural biotechnology and public perceptions. AgBioForum, 1(1), 38-39. Available on the World Wide Web: http://www.agbioforum.org.

jump to top             back to Gideon Notables